Investment Thesis
TELA Bio exhibits a critical solvency crisis with negative shareholders' equity (-5.2M) and insufficient operating cash flows (-11.2M annually) to service 55.9M in debt, creating severe financial distress risk. While strong gross margins (65.7%) and revenue growth (+15.8% YoY) indicate product viability, the company faces insolvency within 3-4 years at current burn rates unless achieving rapid profitability or securing dilutive capital.
Strengths
- Strong gross margin of 65.7% demonstrates product pricing power and operational efficiency in manufacturing
- Revenue growth of 15.8% YoY shows market traction and demand for surgical products
- Cash position of 39.5M provides near-term operational runway versus current burn rate
Risks
- Negative shareholders' equity of -5.2M indicates technical insolvency; liabilities exceed assets
- Operating cash burn of -11.2M annually is unsustainable with only 3.5 year runway at current rate
- Debt service impossible from operations (negative interest coverage -7.9x); refinancing risk is acute
Key Metrics to Watch
- Operating income trajectory and path to breakeven; critical to assess narrowing of -55.2% operating margin
- Operating cash flow improvement; company must achieve positive OCF to avoid forced restructuring
- Debt refinancing activity and capital raise announcements; assess dilution impact on remaining equity value
Financial Metrics
Revenue
19.1M
Net Income
-12.3M
EPS (Diluted)
$-0.21
Free Cash Flow
-11.3M
Total Assets
69.9M
Cash
39.5M
Profitability Ratios
Gross Margin
65.7%
Operating Margin
-55.2%
Net Margin
-64.4%
ROE
N/A
ROA
-17.6%
FCF Margin
-59.2%
Balance Sheet & Liquidity
Current Ratio
3.61x
Quick Ratio
2.92x
Debt/Equity
N/A
Debt/Assets
107.4%
Interest Coverage
-7.90x
Long-term Debt
55.9M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-14T09:19:56.519714 |
Data as of: 2026-03-31 |
Powered by Claude AI